AI assistant
Sending…
GRI Bio, Inc. — Director's Dealing 2021
Feb 10, 2021
35409_dirs_2021-02-09_6c0fce54-44e5-4701-9690-9d1638781059.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Vallon Pharmaceuticals, Inc. (VLON)
CIK: 0001824293
Period of Report: 2021-02-09
Reporting Person: Baker David Charles (Director, Chief Executive Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $1.84 | 2028-10-01 | Common Stock (46875) | Direct | |
| Stock Option (right to buy) | $2.20 | 2029-02-05 | Common Stock (61250) | Direct |
More from GRI Bio, Inc.
Regulatory Filings
2026
May 14
Interim / Quarterly Report
2026
May 13
Major Shareholding Notification
2026
Feb 10
Regulatory Filings
2026
Feb 4
Capital/Financing Update
2026
Jan 30
Capital/Financing Update
2026
Jan 30
Annual Report
2026
Jan 30
Regulatory Filings
2026
Jan 28
Capital/Financing Update
2026
Jan 21
Delisting Announcement
2026
Jan 16